Abstract
Hypomyopathic dermatomyositis (HDM) is a rare form of dermatomyositis (DM). Interstitial lung disease (ILD) associated with clinically amyopathic DM (CADM-ILD) or hypomyopathic DM (HDM-ILD) is a rare condition with a more unfavorable prognosis than ILD associated with classic DM (CDM-ILD). There is no effective treatment for HDM-ILD. A 62-year-old woman with a 6-month history of chronic polyarthritis and myalgia presented skin lesions characteristic of DM (erythematous lesion on extensor surface of elbows, Gottron’s papules, V-neck sign) with no clinical muscle impairment (global muscle strength: grade 5). Muscle enzymes (creatine kinase, lactic dehydrogenase, and aldolase) and electroneuromyography (ENMG) were normal. Computed tomography of the chest revealed ILD. Magnetic resonance imaging and muscle biopsy revealed subclinical muscle impairment. High doses of corticosteroids were used without success. As an alternative, 1500 mg/day of mycophenolate mofetil (MMF) was combined with low doses of prednisone, and the patient demonstrated a good clinical response after 3 months of this combination. Twenty-five months after initiating treatment, ILD remains in remission with the use of MMF and a low dose of prednisone. Therefore, MMF can be a good option for the treatment of HDM-ILD.
Similar content being viewed by others
References
Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L et al (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48-49:122–127. doi:10.1016/j.jaut.2013.11.005
Bailey E, Fiorentino D (2014) Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 16(12):465. doi:10.1007/s11926-014-0465-0
Neri R, Barsotti S, Iacopetti V, Tripoli A, d’Ascanio A, Tavoni AG et al (2014) Clinically amyopathic dermatomyositis: analysis of a monocentric cohort. J Clin Neuromuscul Dis 15(4):157–160. doi:10.1097/CND.0000000000000038
Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136(5):1341–1347. doi:10.1378/chest.08-2740
Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H et al (2014) Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 24(4):694–696. doi:10.3109/14397595.2013.874762
Gil B, Merav L, Pnina L, Chagai G (2016) Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol 35(8):2125–2130. doi:10.1007/s10067-015-2928-8
Morganroth P, Kreider M, Werth V (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 62(10):1496–1501. doi:10.1002/acr.20212
Girard C, Vincent T, Bessis D (2013) Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case. Ann Dermatol Venereol 140(10):628–634. doi:10.1016/j.annder.2013.04.083
Ikeda S, Arita M, Misaki K, Mishima S, Takaiwa T, Nishiyama A et al (2015) Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Spring 4:240. doi:10.1186/s40064-015-1013-8
Cao H, Parikh TN, Zheng J (2009) Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 28(8):979–984. doi:10.1007/s10067-009-1152-9
Sun Y, Liu Y, Yan B, Shi G (2013) Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. Rheumatol Int 33(5):1295–1302. doi:10.1007/s00296-012-2545-7
Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R et al (2010) Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29(4):443–445. doi:10.1007/s10067-009-1358-x
Labirua A, Lundberg IE (2010) Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22(6):633–638. doi:10.1097/BOR.0b013e32833f1970
Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14(3):264–274. doi:10.1007/s11926-012-0246-6
Nagata K, Tomii K, Nanjo S, Kubota M, Tachikawa R, Nishio M (2011) Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody. The Journal of the Japanese Respiratory Society 49(1):30–36
Sato S, Kuwana M, Fujita T, Suzuki Y (2011) Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol 22(4):625–629. doi:10.1007/s10165-011-0558-9
Horai Y, Isomoto E, Koga T, Okada A, Kawashiri S, Tamai M et al (2013) Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 23(1):190–194. doi:10.1007/s10165-012-0637-6
Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ et al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26(10):1647–1654. doi:10.1007/s10067-007-0562-9
Ichiyasu H, Horio Y, Tsumura S, Hirosako S, Sakamoto Y, Sakata S et al (2014) Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases. Mod Rheumatol 24(2):361–365. doi:10.3109/14397595.2013.852847
Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M (2013) Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 144(6):1934–1936. doi:10.1378/chest.13-0186
Sasaki O, Dohi M, Harada H, Imamura M, Tsuchida Y, Yamaguchi K et al (2013) A case of polymyxin b-immobilized fiber column treatment for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis. Case Rep Med. doi:10.1155/2013/750275
Kakugawa T, Mukae H, Saito M, Ishii K, Ishimoto H, Sakamoto N et al (2008) Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med 47(8):785–790. doi:10.2169/internalmedicine.47.0639
Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M et al (2015) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. doi:10.3109/14397595.2015.1014140
Watanabe R, Ishii T, Araki K, Ishizuka M, Kamogawa Y, Fujita Y et al (2016) Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 26(3):465–466. doi:10.3109/14397595.2015.1012797
Zou J, Li T, Huang X, Chen S, Guo Q, Bao C (2014) Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis 73(8):1591–1593. doi:10.1136/annrheumdis-2014-205278
Li T, Guo L, Chen Z, Gu L, Sun F, Tan X et al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. doi:10.1038/srep33226
Oddis CV (2016) Update on the pharmacological treatment of adult myositis. J Intern Med 280(1):63–74. doi:10.1111/joim.12511
Swigris FJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130(1):30–36. doi:10.1378/chest.130.1.30
Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laqué R, Vilardell-Tarrés M (2011) Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 30(11):1393–1398. doi:10.1007/s10067-011-1823-1
Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S (2016) Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 18(1):123. doi:10.1186/s13075-016-1015-0
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719. doi:10.1016/S2213-2600(16)30152-7
Wallace B, Vummidi D, Khanna D (2016) Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol 28(3):236–245. doi:10.1097/BOR.0000000000000270
Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M et al (2016) Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol 34 Suppl 100(5):170–176
Saketkoo LA, Espinoza LR (2008) Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 168(15):1718–1719. doi:10.1001/archinte.168.15.1718
Saketkoo LA, Espinoza LR (2009) Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 337(5):329–335. doi:10.1097/MAJ.0b013e31818d094b
Iqbal K, Kelly C (2015) Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 7(6):247–267. doi:10.1177/1759720X15612250
Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107(6):890–896. doi:10.1016/j.rmed.2013.02.015
Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640–646. doi:10.3899/jrheum.121043
Gerfaud-Valentin M, Ahmad K, Piegay F, Fabien N, Raphanel B, Cordier JF et al (2014) Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies. Rev Mal Respir 31(9):849–853. doi:10.1016/j.rmr.2014.02.010
Cozzani E, Cinotti E, Felletti R, Pelucco D, Rebora A, Parodi A (2013) Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol 35(6):687–692. doi:10.3109/08923973.2013.833624
Hayashi M, Kikuchi T, Takada T (2017) Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies. Clin Rheumatol. doi:10.1007/s10067-016-3443-2
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The patient signed the consent form.
Disclosures
None.
Funding information
There was no funding institution for this article.
Rights and permissions
About this article
Cite this article
Koyama, R.V.L., Braga, T.K.K., da Silva Dias, G.A. et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. Clin Rheumatol 36, 1919–1926 (2017). https://doi.org/10.1007/s10067-017-3671-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3671-0